James Lynch, M.D.

James W Lynch, M.D.

(352) 733-0111

Current patients:
Log in to MyUFHealth

Publications

Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma.
International journal of radiation oncology, biology, physics
2022

Radiotherapy for extranodal classic Hodgkin lymphoma of the maxillary sinus: Case report and literature review.
Head & neck
2018

How Bureaucracy Can Foster Burnout.
Journal of the American College of Radiology : JACR
2018

The Man in the Vest.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2017

Medical educational culture: introducing patients to applicants as part of the medical school interview: feasibility and initial impact show and tell.
Medical education online
2016

Proton therapy in the management of non-Hodgkin lymphoma.
Leukemia & lymphoma
2015

Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
International journal of radiation oncology, biology, physics
2014

Phase 2 Study of Consolidative Involved-Node Proton Therapy in Patients With Hodgkin Lymphoma: Early Outcomes
International Journal of Radiation Oncology Biology Physics
2013

Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
International journal of radiation oncology, biology, physics
2012

Improving the Therapeutic Ratio in Hodgkin Lymphoma Through the Use of Proton Therapy
Oncology
2012

Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.
International journal of radiation oncology, biology, physics
2012

Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
International journal of radiation oncology, biology, physics
2012

Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
The journal of supportive oncology
2010

Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer's ring.
American journal of clinical oncology
2009

Tumor-Associated S-Phase Fraction Correlates With the Presence of C-Myctranslocation in Aggressive Cd10-Expressing B-Cell Lymphomas and May Predict Their Clinical Course
Modern Pathology
2008

Tumor-Associated S-Phase Fraction Correlates With the Presence of C-Myc Translocation in Aggressive Cd10-Expressing B-Cell Lymphomas and May Predict Their Clinical Course
Modern Pathology
2008

Tumor-Associated S-Phase Fraction Correlates With the Presence of C-Myc Translocation in Aggressive Cd10-Expressing B-Cell Lymphomas and May Predict Their Clinical Course
Modern Pathology
2008

Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism.
Clinical lymphoma & myeloma
2007

Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.
American journal of clinical oncology
2007

Lethal midline granuloma-nasal natural killer/T-cell lymphoma.
American journal of clinical oncology
2006

Potential influence of health systems in accrual to clinical trials in lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005

Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005

A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma.
American journal of clinical oncology
2005

Paraneoplastic manifestations of lymphoma.
Clinical lymphoma
2004

Management of neurotropic low-grade B-cell lymphoma: report of two cases.
Head & neck
2003

Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
American journal of clinical oncology
2002

Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
American journal of clinical oncology
2002